4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $30.63.

FDMT has been the subject of several research reports. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, March 7th. Chardan Capital dropped their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Leerink Partners reduced their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th.

4D Molecular Therapeutics Trading Down 4.0 %

NASDAQ FDMT opened at $4.11 on Monday. The business’s 50-day moving average price is $4.90 and its 200 day moving average price is $7.78. 4D Molecular Therapeutics has a twelve month low of $3.73 and a twelve month high of $36.25. The company has a market capitalization of $190.30 million, a PE ratio of -1.44 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in 4D Molecular Therapeutics during the 4th quarter valued at approximately $50,000. PNC Financial Services Group Inc. increased its holdings in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after purchasing an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $56,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.